Page last updated: 2024-12-06

1-(4-carboxyphenyl)-3,3-dimethyltriazene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(4-carboxyphenyl)-3,3-dimethyltriazene, often referred to as **CPTA**, is an interesting molecule that has garnered attention in research due to its potential applications in various fields. Let's break down its structure and significance:

**Structure and Properties:**

* **Structure:** It's a triazene derivative with a carboxyl group attached to a phenyl ring, giving it a unique combination of properties.
* **Properties:**
* **Water-soluble:** The carboxyl group allows CPTA to dissolve in water, which is important for biological studies and potential therapeutic applications.
* **Photolabile:** When exposed to UV light, CPTA readily decomposes. This characteristic is crucial for its use in photochemistry and photodynamic therapy.

**Research Importance:**

* **Photodynamic Therapy (PDT):** CPTA's photolability makes it a potential photosensitizer in PDT. This therapy uses light to activate a drug that selectively targets and destroys cancerous cells. CPTA's ability to generate reactive oxygen species (ROS) upon light exposure makes it a promising candidate for this application.
* **Bioconjugation:** CPTA's carboxyl group allows it to be easily conjugated to other molecules. This makes it a valuable tool for bioconjugation, which is essential for developing targeted drug delivery systems and diagnostics.
* **Chemical Synthesis:** CPTA is a versatile building block for synthesizing other bioactive molecules. Its unique structure and reactivity make it attractive for exploring new chemical reactions and creating novel compounds.
* **Metal Complexation:** CPTA can bind to various metal ions, leading to the formation of coordination complexes. These complexes have potential applications in catalysis, sensing, and materials science.

**Ongoing Research:**

Currently, research on CPTA is focused on:

* **Optimizing its properties** for enhanced PDT efficacy, including increasing its photostability and improving its targeting capabilities.
* **Developing new applications** for CPTA, such as its use in bioimaging, drug delivery, and nanomaterial synthesis.
* **Understanding its biological effects** in depth to ensure its safety and effectiveness.

**In conclusion,** 1-(4-carboxyphenyl)-3,3-dimethyltriazene (CPTA) is a versatile molecule with exciting potential in various research areas. Its unique combination of photolability, water solubility, and conjugatable properties makes it a valuable tool for developing innovative solutions in medicine, chemistry, and materials science.

1-(4-carboxyphenyl)-3,3-dimethyltriazene: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23606
CHEMBL ID422037
CHEMBL ID4785461
SCHEMBL ID4060546
SCHEMBL ID8655588
MeSH IDM0097280

Synonyms (42)

Synonym
benzoic acid,3-dimethyltriazeno)-
nsc226089
7203-91-0
nsc228635
nsc-226089
1-(4-carboxyphenyl)-3,3-dimethyltriazene
3,3-dimethyl-1-(4-carboxyphenyl)triazene
1-p-karboxyfenyl-3,3-dimethyltriazen
wln: t3nnnj a1 b1 cr dvq
nsc-228635
cb-10-277
1-(4-carboxyphenyl)-3,3-dimethyltriazine
nsc 228635
brn 0910024
nsc 226089
1-p-karboxyfenyl-3,3-dimethyltriazen [czech]
cb 10-277
benzoic acid, p-(3,3-dimethyl-1-triazeno)-
benzoic acid, p-(3,3-dimethyltriazeno)-
benzoic acid, 4-(3,3-dimethyl-1-triazenyl)-
p-(3,3-dimethyltriazeno)benzoic acid
kyselina p-(3,3-dimethyl-1-triazeno)benzoova [czech]
4-[(1e)-3,3-dimethyltriaz-1-en-1-yl]benzoic acid
STK021840
CHEMBL422037
4-(dimethylaminodiazenyl)benzoic acid
AKOS005379243
unii-b1cba7h4fg
kyselina p-(3,3-dimethyl-1-triazeno)benzoova
b1cba7h4fg ,
SCHEMBL4060546
SCHEMBL8655588
cb10-277
1-p-carboxyphenyl-3,3-dimethyltriazene
DTXSID70866135
1-(4'-carboxyphenyl)-3,3-dimethyltriazene
cbi0-277
cb i0-277
4-(3,3-dimethyl-1-triazen-1-yl)benzoic acid
benzoic acid, 4-(3,3-dimethyl-1-triazen-1-yl)-
CHEMBL4785461
(e)-4-(3,3-dimethyltriaz-1-en-1-yl)benzoic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" DM-COOK's greater chemical stability might be an advantage, as the decomposition of DTIC is thought to lead to products responsible for some toxic effects in humans."( Comparison of the antitumor activity of DTIC and 1-p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt on murine transplantable tumors and their hematological toxicity.
Colombo, T; D'Incalci, M, 1984
)
0.27

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies were performed with 13 courses which included all dose levels."( Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion.
Calvert, AH; Foster, BJ; Gumbrell, LA; Jenns, KE; Newell, DR, 1993
)
0.29
"3-dimethyl-1-triazeno) benzoic acid in the plasma and urine of cancer patients under pharmacokinetic study."( Determination and pharmacokinetic study of 1-p-(3.3-dimethyl-1-triazeno) benzoic acid in cancer patients by capillary gas chromatography.
Li, AQ; Zhao, XL, 2001
)
0.31
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
" At a dosage equitoxic with that of dimethyltriazenes, cyclophosphamide causes the absence of tumor cells in the peritoneal cavity and in the brains and livers of mice bearing P388 and L1210 leukemias."( Infiltration of liver and brain by tumor cells in leukemic mice: prevention by dimethyltriazenes and cyclophosphamide.
Giraldi, T; Grill, V; Mallardi, F; Perissin, L; Sava, G; Zorzet, S, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID23490Partition coefficient was determined in octanol-saturated sorenson's pH 7.4 phosphate buffer and buffer-saturated octanol.1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID116631Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 25 mg/kg when 10 % acetone/Oil is given as vehicle1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID109749Minimum dose that causes 50% increase in life span in TLX/5 lymphoma bearing animal1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID132183Maximum increase in life span was measured in B6d2F1 mice after implanting murine leukemia L1210 cells(ic, 10e4 cells) at an intracerebral optimal dose of 80 mg/ (kg day)(qd 1-9)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID116633Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 400 mg/kg1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID116628Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 200 mg/kg when 10 % acetone/Oil is given as vehicle1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID21740Solubility in sorensen's phosphate buffer at pH 7.4 and 25 degrees Centigrade.1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID1132822Antitumor activity against mouse L1210 cells allografted in mouse assessed as increase of host lifespan1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.
AID116630Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 25 mg/kg1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID116626Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 12.5 mg/kg1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID116634Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 50 mg/kg when 10 % acetone/Oil is given as vehicle1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID23244Partition coefficient (logP)1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity.
AID116624Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 100 mg/kg1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID116635Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 50 mg/kg1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID116623Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 100 mg/kg when 10 % acetone/Oil is given as vehicle1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID116632Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 400 mg/kg when 10 % acetone/Oil is given as vehicle1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID132186Maximum increase in life span was measured in B6d2F1 mice after implanting murine leukemia L1210 cells(ip, 10e5 cells) at an intraperitoneal optimal dose of 39 mg/ (kg day)(qd 1-9)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID116627Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 12.5 mg/kg when 10 % acetone/Oil is given as vehicle1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID19219Partition coefficient (logP)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID116629Percent increase in life span of TLX/5 lymphoma bearing mice at dose of 200 mg/kg1980Journal of medicinal chemistry, Sep, Volume: 23, Issue:9
Tumor inhibitory triazenes. 2. Variation of antitumor activity within an homologous series.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID132737Percent increase in life span was measured in B6d2F1 mice after implanting murine leukemia Ependymoblastoma cells(ic) at an oral optimal dose of 32 mg/ (kg injection)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-199024 (70.59)18.7374
1990's8 (23.53)18.2507
2000's2 (5.88)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.22 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.03 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (10.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]